Home » Bolder Receives Patent for Manufacturing Process
Bolder Receives Patent for Manufacturing Process
Bolder BioTechnology has been issued a patent for proprietary methods developed by the company to manufacture proteins and modified proteins containing unpaired cysteine.
Adding unpaired cysteine residue to a protein allows targeted modification of the protein with compounds such as polyethylene glycol. Bolder said the process will aid in its development of proprietary, long-acting human protein pharmaceuticals.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
11Jul
-
18Jul
-
21Oct